研报掘金丨国海证券：步长制药未来业绩有望重拾稳健，首予“买入”评级

Group 1 - The core viewpoint of the report indicates that Buchang Pharmaceutical achieved a net profit attributable to shareholders of 628 million yuan in the first half of 2025, representing a year-on-year increase of 171.24% [1] - The company's net profit after deducting non-recurring gains and losses was 619 million yuan, reflecting a year-on-year growth of 180.04% [1] - In the second quarter, the net profit attributable to shareholders reached 320 million yuan, marking a year-on-year increase of 172.94% [1]